HIV/AIDS |
More InformationFor regional questions, please contact International Access Operations by e-mail or phone. Email:Access@gilead.com Telephone: +1-650-522-5101 |
The Global NeedApproximately 34 million people around the world are currently living with HIV/AIDS. Combination antiretroviral therapy has enabled many patients to live with HIV as a chronic, manageable disease - yet fewer than half of the more than 15 million people now in need of HIV therapy are receiving it. Within five years, the number of people in need of treatment is expected to grow to as many as 30 million. Nearly all these patients in need will be in developing countries, where almost 95 percent of people with HIV live. Gilead's RoleThe World Health Organization recommends Gilead's once-daily medicines Viread® (tenofovir disoproxil fumarate) and Truvada® (emtricitabine/tenofovir disoproxil fumarate) as components of HIV therapy for patients beginning treatment. To ensure that these medicines are affordable and available in developing countries, Gilead pursues a comprehensive range of HIV-related access activities, including:
Progress to DateThrough our access efforts, 2.1 million patients in the developing world are now receiving high-quality, low-cost branded or generic versions of Gilead's HIV therapies. This represents nearly one-third of all people in developing countries on any form of HIV treatment, and is a tremendous increase in our reach since the Access Program began in 2003. Over the years we have actively worked to adapt and improve our access initiatives, incorporating feedback from many different stakeholders, and we continue to closely monitor our efforts with the goal of expanding access to our medicines to reach as many patients as possible. For More Information |